NGM tabled its NASH program in 2021 after a key trial failure. Now it’s reporting success in a second study

Lei Lei Wu

News Reporter

Bay Area biotech NGM Biopharmaceuticals reported Thursday afternoon that its drug candidate for non-alcoholic steatohepatitis, or NASH, improved results on a liver biomarker blood test in patients with the most severe form of the disease.

But the results come after NGM Bio decided in 2021 against running a pivotal trial for the drug after it failed a mid-stage trial in NASH patients with less advanced forms of the disease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

NGM tabled its NASH program in 2021 after a key trial failure. Now it’s reporting success in a second study

Lei Lei Wu

News Reporter

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

NGM tabled its NASH pro­gram in 2021 af­ter a key tri­al fail­ure. Now it’s re­port­ing suc­cess in a sec­ond study

Lei Lei Wu

News Reporter

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

NGM tabled its NASH program in 2021 after a key trial failure. Now it’s reporting success in a second study

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them